SDI commenced operations in Jeffrey Cheetham’s garage, producing amalgam fillings and selling the products direct to dentists. By 1975, the company had operations in New Zealand, United States and Greece. Following a decade of national and international success, the company listed on the ASX in 1985. A strong focus on research and development has seen SDI develop an extensive portfolio of innovative restorative and cosmetic dental products including fillings, cements, tooth whitening products and associated dental equipment, with market leading positions in various geographies.
SDI has offices and warehouses in Chicago, USA; Cologne, Germany; Dublin, Ireland and a recently commissioned packing facility in Sao Paulo, Brazil, and turns over in excess of $70m annually.
WHY IS SDI TRADING UNDER THE RADAR?
SDI is a relatively small family-controlled and family-run Australian company which competes against some large multinationals. The company has had an operationally challenging past few years with its performance subject to foreign exchange and commodity price fluctuations, and as a result, trades very much under the radar.
SDI has built its reputation as a supplier of high quality amalgam (silver and mercury based) dental products. However, as consumer preferences have shifted towards more visually appealing dental products, there has been a move away from SDI’s original core amalgam products. As a result, SDI has struggled to generate significant sales growth momentum in recent years.
Fortunately SDI’s more recent research and development initiatives have been focused on non-amalgam products, which is where the industry growth is. The company has been developing a more complex glass ionomer product range, as well as composite and whitening products. Given SDI’s historic reliance on amalgam products, the transition from amalgam to non-amalgam product sales has taken some time.
However, with amalgam sales now representing only 36% of total sales, SDI has successfully managed this product mix transition.
All of SDI’s sales growth in recent years has come from non-amalgam products as shown below:
COMPELLING VALUATION
Based on its recent guidance, SDI is trading on a FY16 p/e of around 11x, and on an Enterprise value / EBITDA multiple of 7x. It should be noted that SDI capitalise, rather than expense the majority of their research and development costs, which potentially overstates their reported net profit. However, these valuation metrics suggest to us that SDI is under-valued for a business with a strong global sales reach and solid growth prospects.
SDI is a great example of a small Australian company developing unique intellectual property and achieving global success in its chosen niche market. We believe the stock deserves its position in our emerging global leaders list.
A sell-down by one of SDI’s larger, long term institutional investors has recently provided some liquidity in this somewhat illiquid stock, and has enabled new institutions and shareholders to enter the register. Whilst SDI is very much perceived as being a family run company, there is the opportunity for a stronger non-family aligned shareholder base to now help change this perception.
For many years the company has demonstrated its ability to consistently bring innovative new products to market. With a strong culture of research and development SDI has excellent potential to continue to grow its sales by expanding its product portfolio and its customer reach, and to become a more robust and larger company. We are happy long term shareholders.
